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Glueagon.likc peptidc.I (1,o37) [(:GLP.I(7=3"/}] is ;tn intcstil~ul peptide hormone that has potent insulinotropic activities in rive in response to oral 
nutrients, in the isolatc¢ pcrfused pancreas, and in vitro in cultured B cells, GLP.I('/~3?) receplor binding and GLP.[(7.37).inducad cAMP genera- 
don and hon'none secretion was studied using cell lines producing insulin/B cell (ffrc.I), glucagon,fA cell (INRIGg) .nd somatostatin/D cell (RIN 
1021.B2), I)=)IlGLP.[(7-37) bound spcCific~tlly to both B =lnd D cells but not to A cells, GLP.I('b.37) induced cAMP.forraation in B and D cell-'= 
with a n~aximura response at I0 nraol~l (B ce)ls) nr at |00 ntq'~ol]l (D cells), Insulin secretion from perifused B cells was stimulated by GLP.l(7~37) 
(maxiraura t IO nmol[I) and IO nmoll1,3 LP.1(7-37] released som==tostatin from p~rifused D cells, GLP.[('/=Yl) did not influence cAMP or glucagon 
secretion From A cells. These data iudicate that pancreatic B and D cells, btl[ not the A cells are inlluenced directly by GLP-I[7,-3?) via binding 
to specific receptors. Our findings support =1 model or physiologic regulation or insulin secretion whereby GLP.l(7~37) released from the intestine 
in response to oral nutrients potently stin'lul~tes insulin secretion via an endocrine mechanisra that in turn may be dampened by a faed.back suppres- 
sion b~, the release ofsomatostatm. In addition, supprcssion~ of the secretion of glucagon, a horn'~onc whose actions are countar.rcguhttory to those 
of insulin, raay occur by paracrme mechanisms involving GLP.l(7=3'/).mcdiated stimulation of both insulin and somatostatin secretion, 
Gluclsgon-like I'~ptide.[(7-3?); Receptor; Somatostatin.secreting cell; Pancreatic isl~.l 
I, INTRODUCTION 
The proglucagon gene is expressed in the A cells of 
the endocrine pancreas (Islets of  Langerhans) and the 
neuroendocrine L cells of  the intestine. The translated 
prohormone contains glucagon and 3 additional pep- 
tides: glicentin-related peptide and the glucagon.l ike 
peptides.I and -It [I,2]. The intestinal processing of 
proglucagon results in 3 different forms of  glucagon- 
like peptid¢-I: GLP- I ( I -37) ,  a biologically inactive 
precursor, and two N-terminally truncated peptides, 
GLP- I (7-36) amide and GLP- I (7-37),  both equally po- 
tent in stimulating the pancreatic B cell to generate 
cAMP and to release insulin [3-5]. 
GLP- I (7-37)  is secreted postprandially f rom the in- 
testinal L cells into the circulation [6] whereby it 
stimulates insulin secretion at picomolar concentrations 
in vivo [6] and in ~;itro [4,7] via interactions with 
specific receptors on pancreatic B cells in a glucose- 
dependent manner [4,8,9]. Thus GLP-I(7-37) is an m. 
cretin hormone that may have an important role in 
glucose homeostasis. Up to now it has not been 
established whether or not GLP-I(7-37) influences 
directly hormone secretions from not only the B ceils, 
but also the glucagon (A cells) and somatostatin (D 
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cells) contained within the islets of Langerhans, A and 
D cells represent only a few percent of the endocrine 
cells of  the pancreatic islets and it is difficult to obtain 
experimentally suitable amounts of pure glucagon- and 
somatostat in-producing cells, Therefore, we studied 
GLP-I(7-3'7) receptor-binding, GLP-I(7"37) induced 
cAMP generation and hormone secretion using insulin- 
(/3TC-I), g lucagon-( INRlG9) and somatostatin- 
(RIN 1027-B2) producing cell lines 
2. MATERIALS  AND METHODS 
2, 1. Peptides 
Synthetic GLP.I(7-37) was from CaI-Bio (Mountain View, CA) 
and [~2SllGLP-I(7=37) was prepared as described [3]. Synthetic por- 
cine GIP and glucagon were from Bachem (Philadelphia, PA), 
2,2. Cell culture 
dTC-I cells [10], RIN 1027-B2 cells [11] and INRIG9 cells [12] were 
grown in RPMI medium supplemented with 10°7o fetal bovine serum, 
507o horse serum, I00 U/ml penicillin and 100 ~g/ml streptomycin i  
a 95070 2 and 507o CO2 humidified atmosphere. 
2.3, Receptor bindin8 studies 
After gentle trypsinization cells were washed twice with 
Krebs-Ringer.buffer (KRB) (pH 7.4) supplemented with 10 rnM 
Hepas and IO70 human serum albumin (Sigma) and were incubated in 
this medium for 30 rain at 37°C, Unlabeled GLP-I(7-37) (50 ~tl, final 
concentration 10 pmol/I to I uraol/I) and labeled GLP-1(?-37) tracer 
(50 #1, 20 000 cpra) were added to 200 ~.1 cell suspension with a S rain 
time interval. Incubations ware carried out for 30 rain at 37°C and ter- 
minated by centrifugation (I rain, 10 000 rpra). The supernatant was 
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Fig, l; Displacement of bindingof [!~I)GLP.I(?-3?) by GLP.I(7-3?) 
from ffrC.l cells (O---O, n,.4) and RIN I027-B2 cells (H ,  
n = 4), and by 81acagon from ~TC.2 ceils (O.---Cl, .  = 4), 
carefully aspira ted and the radioactivity bound to the pellet was deter. 
mined usinB a gamma counter, Specific binding was defined as total 
binding minus binding in the presence of I/,mol/I GLP.IC/-37) and 
expressed as the percent of binding in the absence of GLP.I(7-3?),  
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ml/mln. The omflo~ needle w,~ ¢ofln¢¢t~d to ~ perl'=t=lll¢ pump that 
was adjusted IO 0,6 mVmtn. ^ r te r ,  basal l'~rlod (10 rain) m.~dia were 
ch~l~lled to buffer ,.'oe, latnlfftl the lest ~,ubtialwet a Indiealed, One, 
mtnut~ frm;tton~ w~re collected and e~¢h frt~¢tton was assayed for lh~ 
resf.c~:tlve horl~o.e ¢on~em|'alioD, Hormone secretion data are ex. 
pre'Lwd a~, pcr¢¢n! of the averal!e sewetiOn values durinll the last $ mln 
of the: unslimulated period (Fit, s 2 and 3). Int¢l|rated secresior~ value't, 
area u.der th~ curve (AUC). oblahwd were calculated by addhion of 
the per~emal!e v=~lnes durlnll tl~' first (I-10 rain) and the second 
( l i -20 rain) phase (Tablet I I  and liD. 
2.6, R#dioint/nllno¢=sa, t~ 
Insulin was determined by radiolmmunoas'Lay udn$ nn antiserum 
rai~cd in rabbits aMain~t pork Insulin (Stilton) and pork insulin (SiMma) 
as standard [13|, Glucalion was determined witl~ a radlolmmtmoassay 
using a rabbh antiserum and synthetic lh|caSols as standard [141, 
Somatost~tin was measured by radioimmunoassay with a rabbit t,n. 
tiso|natostasia arltiser~lln (Immunonuclear) and synthetic 
somatostatin as standard (lm|nunonuclear, (13)). Cyclic AMP was 
determined using a rabbit anti.caMP antiserum (Chcmicon, El 
Sesundo, CA), cAMP (Si,lma) as standard [IS], and samples were 
acelylated wilh 20 itl Iriel ~ylamlne/acetic anhydride i:3 (vollvol), In 
all 4 sysi¢lSSS bound arid free l{iland were |leparalett with dexlran- 
coated charcoal, Inter. and intra-a.ay variance for all assay systems 
were within 12%, 
2,7, Sfalislics 
Data are 81yen a. mean ¢ standard error of {.) experiments. When 
indicated Student's t.tes[ was used for statistical analysis, Statistical 
significance was set at the 5% level. 
2,4, Static incubation experimems (¢,4 MP release) 
Two days before the experiment approximately 5 x 10 ~ cells were 
transferred to each well of 24 well plates, At the beginning of the ex. 
perirnent cells were washed twice with KRB buffer and incttbated in 
this medium ( lml)  for 60 min (37=C). Then the buffer was changed 
to a buffer (300/~1) containing the test substances a  indicated for 30 
rain. The entire supernatant was lyophilized and reconstituted in 
assay buffer for caMP determination. 
2.5. Per6fissiott e.vperiments fizormot~e release) 
The day before the experiments ca 2 x i0 e cells were planted into 35 
mm diameter culture dishes. Cells were washed twice with KRB buffer 
supplemented with 0.1% human serum albumin (pH 7,4, 37°C) and 
incubated in this medium for one h (37°C), Three inflow needtes and 
one outflow needle were inserted in the roof of the culture dish 
prepared with the respective holes (angle 90 ° each). The culture dishes 
were placed on a temperature-regulated plate (37°C) and each inflow 
needle was connected with one syringe containing KRB buffer plus the 
respective t st substances, A Harvard Apparatus pump 22 (Harvard 
Apparatus, South Natick, MA) generated a constant flow of 0,2 
3. RESULTS 
3,1. Bindi~g experiments 
GLP- I ( '7-37) inhibi ted specific b ind ing of [12SI]GLP- 
I(7-37) to /~TC-I cells and RIN 1027-B2 ceils in a 
concent ra t ion .dependent  manner  (Fig, 1). Non.speci f ic  
b ind ing  (bound radioactivity in the presence of  I ~mol / l  
GLP- I (7 -37) )  was 19,8070 (/3TC-1 celts) and 18,6°70 (RIN 
1027-B2 cells), The  Ka (50% inhibi t ion)  was 3.3 nmol / l  
(/~TC-1 cells) and  3.5 nmol / l  (RIN-102'7-E2 cetls). 
G lucagon,  but  not G IP  inhibited b ind ing of  [t2sI]GLP- 
I (7-37) to fgTC-I cells only weakly: 100 nmol / l ,  32% in- 
h ib i t ion;  10 nmol / l ,  1 1% inhib i t ion (Fig, 1), There was 
no detectable b ind ing of [12sI]GLP-l(7-37) to INR1G9 
cells, 
Effect of GLP-1(7-37)on cAMP secretion from ~TC-I, 
Table I 
INRIG9 and RIN 1027-B2 cells, Four to six independent experiments were performed m 
triplicate for each condition 
Glucose GLP-1(7-37] 
(mmol/I) (-log M) 
cAMP secretion (fmol/well/30 rain) 
8TC-I INRI G9 RIN 1027.B2 
0 0 
5 0 
5 11 
S 10 
5 9 
5 8 
5 7 
5 6 
0 8 
38 = 2 1674 ± 155 576 z 158 
39 ± 18 2055 ± 117 778 ± 289 
38 ± 18 576 ± 142 
63 ± 30 421 ± 147 
140 ± 45* 1223 ± 485 
330 ± 136' 1524 ± 69 1827 ± 353* 
i29 ± 42 + 2624 ± 376 + 
53 ± 18* 1754 ± 593* 
41 = 4 926 ± 123 
*significant difference vs control experiments (5 mmol/I glucose) 
#significant difference vs experiments with 10 nmol/l GLP.I(7-37) 
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Fig, 2, Effect of GLP-I(7-37) on glucose-stimulated (5 mrnoll]) insulin release from perifused ~TC-I cells, (A) 5 mmolll glucose (n =6), (B) 5 
mmol/I glucose ~- 10 pmol/I GLP-I(7-37) (n=6), (C) 5 mrnol/l glucose + 100 pmol/l GLP.I(7-37) (n=6), (D) 5 rnmol/l glucose + 1 nmol/l 
GLP-1(7-37) (n=6), (E) 5 mmol/l glucose + 10 nrno]/I GLP.I(7-37) [6], (F) 5 mmol/l glucose -~ 100 nmol/l GLP.[(7-37) (n=3). 
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Table II 
Ii)|ellrated Imulin se<retory re,pones to #uq:ow and ¢3LF,It?-]'/) from perifuwd xrc.I ,wl l ,~ dttrlnl; the I'ir)l (I-IO rain) anti the ,~¢~Und phnw 
(I I=20 mtn) 
~lttcQs¢ GLP, I ( I=37) - Ftr'st phase ' - 
(mmolll} (-loj MI (AUC~ [-I0 mln) 
0 0 lO~t~ = 9S 772 = #0 
S 0 23J0 • 226" IO~9 ~ 12S 
10 ~ 2~gl ¢ 222 • 1359 ¢ ~a 
20 0 4299 z 364 m 13~6 ¢ 144 
S I I  2014 = ~#7 1299 ¢ 194 
5 l0 20)~ z $~ 1~42 ¢ 44 
9 3299 x 671" 17~? = 267 
8 49~0 ~ |057" 2204 ~ $18 
5 7 3068 z ~ 17~1 ± ~4 
0 8 )302 ¢ 191 8~$ = B8 
(AUC/ i  I ,.20 mini 
~$111nificant difference vs control expertment~ (buffer alone) 
'Significant difference vscontrol experiments ($ mmol/I IllUCOSe) 
AUC a area under the curve, the int•rated measttrement of insulin lecretion, 
3,2. cAMP secretion 
Incubation of BTC-I, INR IG9 and RIN 1027-B2 cells 
with buffer supplemented with 5 mmol/i glucose had 
no effect on secreted cAMP levels compared to ex- 
per iments with buffer alone [Table 1], 0LP-1(7-37) in- 
duced cAMP secretion from BTC-I cells in a 
concentration.dependent manner with a maximum at 
10 nmol/i as reported previously [16] and from RIN 
1027-B2 cells with a maximum at 100 nmol/l, GLP- 
I(7-37) had no influence on cAMP secretion from 
INRIG9 cells, The biphasic response of cAMP forma- 
tion with an attenuated response at higher concentra- 
tions of GLP-I(7-37) was shown in earlier studies of the 
effect of GLP-I(7-37) on a rat B cell line (RIN 1046-38 
cells, [17]), The diminished response at higher concen- 
trations of ligand is due to a rapid homologous desen- 
sitization of the GLP-I(7-37) receptor (H.C. Fehmann 
1000- 
800 
1 
600 
= 
400 
200 
o ¢o a.o 3'o 
t (mln) 
Fig, 3. Effect of 10 nmol/l GLP-I(7-37) (C>----O; n=6) on glucose- 
induced (5retool/l) somatostatin release from perifused RIN 1027-B2 
cells, Control experiments (5 mmol/l glucose (.- --), n=6), 
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and J,F. Habener, unpublished observations), In the 
absence of glucose GLP.I(7-37) had no effect on cAMP 
secretion from ~tTC.i and RIN 1027-B2 cells, 
3,3, Hormone secretion 
I~TC-I cells secreted insulin in response to glucose in 
a concentration-dependent manner as described from 
static incubation experiments with this cell line [18]. 
The secretory pattern was monophasic as known from 
studies with another glucose.responsive cell line, HIT- 
T-15 [19] and insulin secretion values returned to basal 
levels after 10=12 min in the continuous presence of 
glucose (Fig. 2), Addition of GLP-I(7-37) enhanced in- 
sulin secretion concentration-dependently during the 
first phase (1-10 mini with a maximum at 10 nmol/I 
and induced a small second phase of insulin release 
(Fig. 2, Table II). A similar phenomenon has been 
observed in studies with HIT cells and IBMX [19]. The 
insulinotropic action of GLP-I(7-37) was glucose. 
dependent (Table II). 
Perifusion of RIN I027-B2 cells with KRB buffer 
supplemented with 5 mmol/l glucose induced 
somatostatin release for 12 rain. Addition of I0 nmol/] 
GLP-I(7-37) enhanced the somatostatin response dur- 
ing the first 5 rain in a glucose-dependent manner (Fig. 
3; Table Ill). lO mmol/l glucose plus 10 mmol/l 
arginine stimulated glucagon release from IN RIG9 cells 
with a monophasic pattern for 15 rain. Additon of I0 
nmol/l GLP-I(7-37) had no effect on glucagon secre- 
tion (AUC; first phase: controls: 2975 ~: 199, GLP- 
I(7-37): 2574 ~- 219; second phase: controls: 1477 =: 
226, GLP-I(7-37): 1771 _ 189). 
4. DISCUSSION 
The insulinotropic action of GLP-I(7-37) in rive and 
in vitro is well established and GLP-I(7-37) is believed 
to represent an important mediator of the entero- 
insulinar axis and glucose homeostasis. Using the 
Volume 2'79, nt~mber 2 FEB$ LETTERS Februmry I~1 
Table I I I 
Inlellraled ~omato~lmlln ~¢¢rclory retpom~ to i!lu¢ow and GLP.I(7..I?) from pcrll'u~¢d RIN i0.11.11].¢d1~ durtnll the rlr~, (I-IOI ,ntl ¢lw ~ond 
ph~e (I 1-20 mlnl 
tmmol/ll (-IOlt NIl (AUC/ I -  10mini (^UC/I  I-2O mini 
0 0 9)? ~ 12~I 11~,7 ¢ 161 
0 I~ ~911 ,¢ 63 741 .¢ 179 
.~ II ,I},,~2 = 2~12' 10119 .~ 10S 
'$i[Inlficanl diff~ren~:e vs  comrol expcrlmenls (J, mmol/l illu,~'us¢) 
AUr,.* ,., arc'~ under the curve, the Inteilratetl mcasttrenlent of somatost~lin se~:rction. 
glucose.responsive cell line/3TC- 1 wc demonstrate the 
presence of' a specific receptor for GLP-I(7-37} on these 
cells (K,I 3.5 nmol/I) as was reported previously in 
studies with the pancreatic B cell lines RINmSF [8] and 
RIN 5AH [91. The different cell lines used might ac. 
count for the slightly different g,~s (RINmSF cells: 204 
pmol/I [8], RIN SAH: 3,3 nmol/I [9], ~TC-i cells: 3.S 
nmol/l). The failure of GIP to compete with binding of 
radiolabeled GLP-I(7-37) suggests the presence of 
distinct receptors for GLP-I(7-37) and GIP on pan- 
creatic B cells. In addition, our data demonstrate that 
GLP-t(7-37} stimulates concentration.dependently 
cAMP and insulin secretion from ISTC-I cells as 
reported previously in studies with this and other B cell 
lines [8,6,171. 
Previous tudies with rat islet cell monolayer cultures 
[20] and the perfused rat pancreas [211 suggested a
somatostatin.releasing action of GLP-I(7-37). Our data 
provide evidence for a direct role of GLP-I(7-37) in the 
regulation of pancreatic somatostatin release: RIN 
I027-B2 cells possess pecific receptors for t"ILP.I(7-37) 
with nearly identical binding characteristics ompared 
with insulin-~roducing cell lines /3TC-I, RIN 5AH !9] 
Indirect Patacrlne Mogel for "Suppression" 
of Glucagon Secrotlon Dy GLP.I{7.37) 
Core  Mant le  
l o 
Glueagon 
Fig. 4. Model for postulated negative feedback suppression of 
glucagon secretion by the actions of GLP.I(7-37) to stimulate secre- 
tion of both insulin and somatostatin via specific receptors in B and 
D cells. Because of the portal blood flow from the core to the mantle 
of the pancreatic islet, it is envisioned that the known suppressive ef- 
fects of insulin and somatostatin on glucagon secretion are mediated 
by paracrine naechanisms. Somatostatin may in theory feed back 
neaatively to clampen the GLP.l(7-37).induced insulin secretion, 
perhaps by an endocrine pathway. 
and, RIN mSF [8]. Thes~ data su88est hat the same 
receptor is expressed on Insulin. and somatostatin- 
producing cell lines. In addition, GLP-i(7-37) induces 
cAMP and somatotstatin secretion from RIN 1027.B2 
cells. "These observations extend those of earlier reports 
that glucose is a stimulator of pancreatic somatostatin 
secretion [22] and that cAMP is involved in tile 
stimulus-secretion coupling of tile pancreatic D cell 
[23], 
Some controversy exists whether or not GLP-I(7-37) 
influences pancreatic A cell secretion, Studies with the 
isolated perfused rat pancreas [4] and rat p~ancreatic 
islet cell monolayer cttltures [20] revealed no effect of 
GLP-I(7'37) on pancreatic glucagon release, whereas 
other report: using the isolated pig [24] and rat pan- 
crease [5,25] and isolated rat islets [26] described, corn. 
pared to the insulinotropic action, a weak glucago. 
nostatic action of GLP-I(7-37) that requires I0 to 
100.fold higher GLP.I(7-37) levels than the insulino- 
tropic erfe,:t, Our data t~ow indicate that INRIG9 
(glucagon-producing) cells do not possess binding sites 
for GLP-I(7-37), and presumably binding sites are ab- 
sent on pancreatic A cells. It is well established that at 
least in the rat pancreas a directed blood flow from the 
B cells to the A cells and then to the D cells exists and 
in this va~cular compartment insulin represents a 
physiological inhibitor of glucagon secretion [27], 
There is also strong evidence that somatostatin sup- 
presses A cells by paracrine mechanisms [28]. Thus, the 
glucagonostatic a tion of GLP-I(7-37) in the perfused 
pancreas can be explained by the stimulation of both in. 
sulin and somatostatin release. This concept is sup- 
ported by ~he recent finding that GLP-I(7-36) amide 
does not suppress glucagon secretion in perfused pan- 
creata frown streptozotocin-treated rats which had a 
50% reduced insulin release during stimulation with 
GLP-l(7-36)amide or GIP compared to non-diabetic 
controls [29]. In addition, such paracrin¢ mechanisms 
seem to be involved in the reported inhibitory action of 
GLP-I (7-37) on glucagon gene transcription i  isolated 
rat islets [26] and the hamster glucagonorna cell line 
iNR.i(39 [:30i. 
Taken together our data support he concept of GLP- 
I(7-37) as an important intestinal factor in the regula- 
tion of hormone secretion from the endocrine pancreas. 
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In addit ion to the stimulation o f  insul in release from B 
cells GLP- l (? -37)  can also stimulate somatostal in 
release by specific receptors present on D cells but is 
without direct effect on the A cells (Fig, 4). The 
demonstration of  the existence o f  functional GLP .  
I(7-3.'7) receptors on D cells raises the possibility that 
with respect to GLP- I ( ? -37)  the entero-islet axis may in. 
valve more tha~ just the aullmentation of  insulin score, 
tion, It seems reasonable to postulate that the effect of 
GLP- I(7-37) to stimulate somatostatin secretion is 
designed to dampen the stimulation of  insulin secretion 
invoked by GLP- I (7-37) ,  In addit ion, ~he combined 
secretion of  both insulin and somatostatin augmented 
by GLP- I (7-37)  may act to suppress by paracrine 
inechanlsms the secretion of  81ucagon, a known potent 
hormon~ that is counter-regulatory to the metabolic ac- 
tions of  insulin, 
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